Verastem,Inc. (NASDAQ:VSTM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k

6 years ago

Verastem,Inc. (NASDAQ:VSTM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

OnMay30, 2018, Julie Feder resigned as Chief Financial Officer of Verastem,Inc. (the “Company”) to pursue other professional opportunities.

Effective May31, 2018, Daniel Paterson, 57, the Company’s Chief Operating Officer, will serve as the Company’s principal financial officer and principal accounting officer on an interim basis. The Company has initiated a search to identify and recruit a new candidate for the role of Chief Financial Officer.

Information regarding Mr.Paterson required by Items 401(b), (d), (e)and Item 404(a)of Regulation S-K was previously reported in the Company’s annual report on Form10-K filed on March13, 2018 and is incorporated by reference herein.

About Verastem,Inc. (NASDAQ:VSTM)
Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company’s programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company’s VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company’s VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.